Brief: Mirum Pharmaceuticals Says Health Canada Authorizes Livmarli For Cholestatic Pruritus In Progressive Familial Intrahepatic Cholestasis (Pfic) Patients
05/02/2026 13:20
Feb 5 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS ANNOUNCES HEALTH CANADA AUTHORIZATION OF LIVMARLI® FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) Source text: ID:nBw76fPJha Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX